Ranked among the highest-rated Harvard Medical School CME courses, past participants consistently report that this program has inspired and improved their clinical practice and outcomes. Here are a few comments from recent attendees of this course:
“I now use more evidence-based interventions for various issues such as coronary artery disease, pericarditis, pulmonary embolism.”
“As an inpatient cardiology provider, every topic presented [in this course] applied to my patients--from structural heart to arrhythmias--and was exceptional.”
“This course equipped me to better manage diabetes, pericardial disease, valve disease, arrhythmia and heart failure patients.”
“I am practicing better management of resistant hypertension, I have a better knowledge of the early signs of DHF, have much improved knowledge of NOACs, have updated my interpretation of the EKG and am better able to manage patients with afib and PCI.”
“I am employing new therapies for orthostatic patients and have a better understanding of when to refer the CHF patient for newer therapies.”
“This course has updated my practice in many ways: 1. Management of implantable devices - will refine my approach with colleagues and advocate more consensus/planning regarding infected PPM leads, etc., with evidence to back this up…. 2. Approach to pericarditis and steroid regimens/weaning as well as follow-up 3. I will adjust my threshold in stopping anticoagulation in elderly patients with falls risk and better balance this consideration with their measurable stroke risk (we tend to be overcautious with anticoagulation in this particular patient group) 4. Duration of anticoagulation + longer term management of patients post significant VTE.”
“The talks that concentrated on my everyday clinical practice and helped me make better clinical choices or therapeutic and or diagnostic choices were amazing.”
“The assessment of infiltrative causes for heart failure is now much more part of my diagnostic workup in heart failure.”
“Changes to my practice from this course: 1. I consider ordering home sleep studies if patients' insurance allows it. 2. I am revisiting appropriate BP goals for certain patient populations. 3. I have become more adept at choosing which NOAC based on clinical scenario. 4. I am staying abreast of benefit profile of certain diabetic agents as they relate to cardiovascular disease.”
“The discussions pertaining to anticoagulation, pulmonary embolism, amyloidosis, and congenital heart disease were outstanding.”
“The faculty were exceptional in their summary of the state of the art in each area covered in the course.”
“There are several areas where I have changed my practice after knowledge I gained during the course, especially when to refer for advanced therapies in heart failure and pulmonary hypertension.”
“I am paring down dual and triple rx for CAD/AF patients; making earlier referrals for advance heart failure; collaborating with IM and Endo for more use of disease-altering therapy in diabetics with heart disease; and prescribing longer duration of anticoagulation after provoked pe/dvt.”
“The cardio-oncology topic was really helpful – I plan to do research on the decline of cardiac function among patients receiving chemotherapy and radiation.”
“I have started to use more tailored approaches to lipid and anti-inflammatory management in my practice, and am more comfortable with the indications and use of thrombolytic therapy in patients with PE.”
“This course has updated my CHF, AF, VTE/PE order sets. We are developing order sets for anticoagulant reversal, and reviewing policies to reduce 30-day readmission for CHF.”
“This course has simply reinvigorated me to provide optimal care for patients.”
“The education from this course has led to changes in the management of pulmonary embolism, pericarditis, a.fib, the duration of triple antithrombotic therapy in PCI/a.fib heart failure surveillance, cardiac risk stratification and surveillance in pregnancy, and I am fine tuning VHD management, especially in TAVR cases.”
“I have implemented evidence-based oral AC and antiplatelet strategies, and updated my early treatment of CV risk factors-- esp obesity, DM and HTN.”
“I am a hospitalist with considerable teaching responsibility for students through Sr residents and this updated information will be a huge help in properly educating our learners.”
“Hearing from thought leaders and pioneers in the field is always a memorable experience.”
“This course has modified my management of pacemaker and ICD leads during change-out procedures. It has also Improved my medication choices for certain conditions such as heart failure and diabetes mellitus. Be more aware of amyloid, especially in African American patients."
“I have made a number of adjustments in clinical decision-making, e.g. within anticoagulation, pericardial disease, EP, amyloidosis, etc.”
“The interaction with top clinicians and seeing how they approach different issues was exceptional.”
